Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity

Purpose Anticancer drug delivery systems are often limited by hurdles, such as off-target distribution, slow cellular internalization, limited lysosomal escape, and drug resistance. To overcome these limitations, we have developed a stable nitric oxide (NO)-releasing nanoparticle (polystyrene-maleic acid [SMA]-tert-dodecane S-nitrosothiol [tDodSNO]) with the aim of enhancing the anticancer properties of doxorubicin (Dox) and a Dox-loaded nanoparticle (SMA-Dox) carrier. Materials and methods Effects of SMA-tDodSNO and/or in combination with Dox or SMA-Dox on cell viability, apoptosis, mitochondrial membrane potential, lysosomal membrane permeability, tumor tissue, and tumor growth were studied using in vitro and in vivo model of triple-negative breast cancer (TNBC). In addition, the concentrations of SMA-Dox and Dox in combination with SMA-tDodSNO were measured in cells and tumor tissues. Results Combination of SMA-tDodSNO and Dox synergistically decreased cell viability and induced apoptosis in 4T1 (TNBC cells). Incubation of 4T1 cells with SMA-tDodSNO (40 µM) significantly enhanced the cellular uptake of SMA-Dox and increased Dox concentration in the cells resulting in a twofold increase (P<0.001). Lysosomal membrane integrity, evaluated by acridine orange (AO) staining, was impaired by 40 µM SMA-tDodSNO (P<0.05 vs control) and when combined with SMA-Dox, this effect was significantly potentiated (P<0.001 vs SMA-Dox). Subcutaneous administration of SMA-tDodSNO (1 mg/kg) to xenografted mice bearing 4T1 cells showed that SMA-tDodSNO alone caused a twofold decrease in the tumor size compared to the control group. SMA-tDodSNO in combination with SMA-Dox resulted in a statistically significant 4.7-fold reduction in the tumor volume (P<0.001 vs control), without causing significant toxicity as monitored through body weight loss. Conclusion Taken together, these results suggest that SMA-tDodSNO can be used as a successful strategy to increase the efficacy of Dox and SMA-Dox in a model of TNBC.

[1]  K. Greish,et al.  The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer. , 2018, Therapeutic delivery.

[2]  K. Greish,et al.  Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer , 2017, Journal of drug targeting.

[3]  Won Jong Kim,et al.  Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Angus P R Johnston,et al.  Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[5]  H. Maeda,et al.  Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. , 2017, Biomaterials.

[6]  Yu-mei Shen,et al.  Controllable release of nitric oxide and doxorubicin from engineered nanospheres for synergistic tumor therapy. , 2017, Acta biomaterialia.

[7]  Y. Ishima,et al.  Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers. , 2017, Biological & pharmaceutical bulletin.

[8]  Zhenxing Liu,et al.  Lysosome Inhibitors Enhance the Chemotherapeutic Activity of Doxorubicin in HepG2 Cells , 2016, Chemotherapy.

[9]  Khaled Greish,et al.  Hypoxia Responsive Drug Delivery Systems in Tumor Therapy. , 2016, Current pharmaceutical design.

[10]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[11]  B. Bonavida,et al.  Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics☆ , 2015, Redox biology.

[12]  D. Herrero-Martín,et al.  "(Not) all (dead) things share the same breath": identification of cell death mechanisms in anticancer therapy. , 2015, Cancer research.

[13]  H. Maeda,et al.  Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide , 2015, Cancer science.

[14]  Zhiping Zhang,et al.  Nitric oxide releasing d-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin. , 2014, Molecular pharmaceutics.

[15]  S. Kumari,et al.  The design of nitric oxide donor drugs: s-nitrosothiol tDodSNO is a superior photoactivated donor in comparison to GSNO and SNAP. , 2014, European journal of pharmacology.

[16]  Pawel A. Janowski,et al.  Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long‐term tracking of acidic vesicles , 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[17]  Samir Mitragotri,et al.  Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. , 2014, Nano today.

[18]  Haijun Yu,et al.  Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. , 2013, Advanced drug delivery reviews.

[19]  Christer S. Ejsing,et al.  Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. , 2013, Cancer cell.

[20]  A. Gadbail,et al.  Nitric oxide and cancer: a review , 2013, World Journal of Surgical Oncology.

[21]  G. Chaudhuri,et al.  Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: implications for breast cancer. , 2013, Free radical biology & medicine.

[22]  H. Maeda.  Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Yi Xiao,et al.  A lysosome-targetable and two-photon fluorescent probe for monitoring endogenous and exogenous nitric oxide in living cells. , 2012, Journal of the American Chemical Society.

[24]  S. Kumari,et al.  The Molecular Design of S‐Nitrosothiols as Photodynamic Agents for Controlled Nitric Oxide Release , 2012, Chemical biology & drug design.

[25]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  G. M. Nagaraja,et al.  A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease , 2012, BMC Cancer.

[27]  Pietro De Camilli,et al.  Dynamin, a membrane-remodelling GTPase , 2012, Nature Reviews Molecular Cell Biology.

[28]  Cahir J. O'Kane,et al.  Complex Inhibitory Effects of Nitric Oxide on Autophagy , 2011, Molecular cell.

[29]  H. Chakrapani,et al.  Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles. , 2010, Molecular pharmaceutics.

[30]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[31]  A. Zylicz,et al.  Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology , 2010, Nature.

[32]  S W Smye,et al.  A mathematical model of doxorubicin penetration through multicellular layers. , 2009, Journal of theoretical biology.

[33]  Subra Suresh,et al.  Size‐Dependent Endocytosis of Nanoparticles , 2009, Advanced materials.

[34]  P. Swaan,et al.  Endocytic mechanisms for targeted drug delivery. , 2007, Advanced drug delivery reviews.

[35]  C. Lowenstein,et al.  Nitric oxide regulation of protein trafficking in the cardiovascular system. , 2007, Cardiovascular research.

[36]  M. R. Miller,et al.  Recent developments in nitric oxide donor drugs , 2007, British journal of pharmacology.

[37]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[38]  J. Stamler,et al.  Nitric oxide regulates endocytosis by S-nitrosylation of dynamin , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Guido Kroemer,et al.  Lysosomes and autophagy in cell death control , 2005, Nature Reviews Cancer.

[40]  K. Kashfi,et al.  Molecular targets of nitric-oxide-donating aspirin in cancer. , 2005, Biochemical Society transactions.

[41]  C. Riganti,et al.  Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. , 2005, Cancer research.

[42]  H. Maeda,et al.  SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[43]  C. Leeuwenburgh,et al.  Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. , 2002, Biochimica et biophysica acta.

[44]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[45]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[46]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[47]  W. Paschen,et al.  Effect of nitric oxide on endoplasmic reticulum calcium homeostasis, protein synthesis and energy metabolism. , 2000, Cell calcium.

[48]  G. Brown,et al.  Nitric oxide and mitochondrial respiration. , 1999, Biochimica et biophysica acta.

[49]  D. Wink,et al.  Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.

[50]  P. Bijlenga,et al.  Uncoupling Protein-3 Expression in Rodent Skeletal Muscle Is Modulated by Food Intake but Not by Changes in Environmental Temperature* , 1998, The Journal of Biological Chemistry.

[51]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[52]  L. Loew,et al.  Physiological cytosolic Ca2+ transients evoke concurrent mitochondrial depolarizations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D L Farkas,et al.  Simultaneous imaging of cell and mitochondrial membrane potentials. , 1989, Biophysical journal.

[54]  E. Mimnaugh,et al.  Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. , 1985, Biochemical pharmacology.

[55]  E. Goormaghtigh,et al.  Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. , 1983, Biochemical pharmacology.

[56]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[57]  V. Turk,et al.  Lysosomes and lysosomal cathepsins in cell death. , 2012, Biochimica et biophysica acta.

[58]  Z. Darżynkiewicz,et al.  Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. , 1994, Methods in cell biology.

[59]  submit your manuscript | www.dovepress.com , 2022 .